Australia Proactively Produces COVID-19 Vaccines

Australia-based CSL announced 'Multiple doses of the COVID-19 UQ-CSL V451 vaccine candidate have already been manufactured at the Broadmeadows facility and are held in readiness to progress the vaccine to Phase 2b/3 clinical trials.'

This press statement issued on November 8, 2020, indicates the University of Queensland produced vaccine candidate combines the adjuvant technology MF59 to improve immune response, reduce the amount of antigen needed for each vaccine, and enable more doses to be manufactured more rapidly.